drugset / Trial / NCT02758132
Denosumab Plus Enzalutamide, Abiraterone and Prednisone Compared to Denosumab Plus Enzalutamide Alone for Men With Castrate Resistant Prostate Cancer (CRPC) With Bone Metastases
Non-randomizedParallel-groupOpen-labelTreatment
Summary
This is a correlative study to characterize serum metabolites associated with bone deposition, growth and turnover in patients with newly diagnosed metastatic CRPC who are not currently receiving bone targeting agents.
Timeline
- Start
- 2016-03-01
- Primary completion
- 2016-09-06
- Completion
- 2016-09-06
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Comparator | Abiraterone acetate | Small molecule | 1000 mg | Oral |
| Comparator | Prednisone | Other / unclassified | 5 mg | Oral |
| Comparator | Denosumab | Monoclonal antibody | 120 mg | Subcutaneous |
| Comparator | Enzalutamide | Other / unclassified | 160 mg | Oral |